Previous 10 | Next 10 |
Inovio Pharmaceuticals Inc. (INO) is expected to report $-0.13 for Q3 2023
2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...
Q3 2023 total revenue of $48.6 million Recorded net loss of $21.8 million; delivered positive adjusted EBITDA of $4.0 million for Q3 2023 5G Fixed Wireless Access (FWA) revenue represented 23.0% of total revenue and grew 29.0% year-over-year Inseego Corp. (Nasdaq: INSG) (the ...
Steve Harmon will Lead Sales and Marketing Globally for the Company Inseego Corp. (Nasdaq: INSG), a leader in 5G edge cloud solutions, today announced that effective today, Steve Harmon has joined the company in the newly-created role of Chief Revenue Officer of Inseego. Harmon will ove...
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 PR Newswire PLYMOUTH MEETING, Pa. , Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat an...
Inseego Corp. (Nasdaq: INSG), a leader in 5G edge cloud solutions, today announced that the company will release its financial results for the third quarter ended September 30, 2023, after the financial markets close on Thursday, November 2, 2023. The quarterly financial statements and earnin...
2023-10-10 08:47:53 ET More on Inovio Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript) Inovio Pharmaceuticals: Tightening The Ship, Finding An Inflection Point Inovio Pharmaceuticals, Inc. (INO) Q2 2023 Earnings...
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program PR Newswire Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission ...
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million PR Newswire -- Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer -- -- Shanghai -based SHC Added to Geneos' Investor Syndicate -- ...
Inseego Corp., a leader in 5G edge cloud solutions, today announced it has appointed experienced technology executive Philip Brace to its board of directors as an independent director. “We are delighted to welcome Phil to our board of directors,” said Jeff Tuder, Chair of Inseeg...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respi...